Literature DB >> 9286718

Effect of magnesium sulfate treatment on neonatal bone abnormalities.

Y Matsuda1, Y Maeda, M Ito, H Sakamoto, N Masaoka, M Takada, K Sato.   

Abstract

OBJECTIVE: It has been reported that neonatal bone abnormalities occur as a result of long-term intravenous magnesium administration (MgSO4) to pregnant women. The purpose of this retrospective study was to evaluate the frequency of such abnormalities and the clinical background of both mothers and neonates. PATIENTS AND METHODS: We reviewed maternal (114 cases) and neonatal (139 cases) charts from all pregnant women who received intravenous MgSO4 administration for preterm labor and preeclampsia between June 1, 1992, and May 31, 1994. All chest X-ray films were obtained within 48 h after birth and reviewed by a doctor who was unaware of the clinical data. Radiolucent transverse metaphyseal bands of the proximal humerus were considered as abnormal. The subjects were divided into affected (group 1 and 1a) and unaffected (group 2 and 2a) groups. Neonates born to pregnant women given no MgSO4 at the same period, were considered as control.
RESULTS: The total number of bone abnormalities in the offspring of mothers receiving MgSO4 amounted to 13 (11.4%). Group 1 consisted of 13 cases and group 2 of 101 cases. In the control group bone abnormalities were not observed (p < 0.05). Significant differences were found between groups 1 and 2 in the gestational ages at the start of MgSO4 administration and at delivery, and in the total duration of administration and doses of MgSO4. Also, cases of multiple pregnancy and pregnancy complicated with impaired glucose tolerance were more prevalent in group 1. According to the results obtained from 139 neonates, cases showing low Apgar and high magnesium score and those receiving respiratory support were more noticeable in group 1a (15 cases).
CONCLUSIONS: The gestational ages and the total doses of MgSO4 in pregnant women were the main factors related to the onset of neonatal bone abnormalities, but other factors also have a possible bearing on the condition. In addition, the cases with onset of bone abnormality seemed to be associated with symptoms attributable to hypermagnesemia of neonates.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286718     DOI: 10.1159/000291492

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  6 in total

1.  Effects of Maternal Magnesium Sulfate Treatment on Neonatal Feeding Tolerance.

Authors:  Meghan K Belden; Sarah Gnadt; Ann Ebert
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Mar-Apr

Review 2.  Overrepresentation of multiple birth pregnancies in young infants with four metabolic bone disorders: further evidence that fetal bone loading is a critical determinant of fetal and young infant bone strength.

Authors:  M Miller; T Ward; A Stolfi; D Ayoub
Journal:  Osteoporos Int       Date:  2014-04-03       Impact factor: 4.507

3.  Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis.

Authors:  Emily Shepherd; Rehana A Salam; Deepak Manhas; Anne Synnes; Philippa Middleton; Maria Makrides; Caroline A Crowther
Journal:  PLoS Med       Date:  2019-12-06       Impact factor: 11.069

Review 4.  Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches.

Authors:  Licia Grazzi; Claudia Toppo; Domenico D'Amico; Matilde Leonardi; Paolo Martelletti; Alberto Raggi; Erika Guastafierro
Journal:  Int J Environ Res Public Health       Date:  2021-02-05       Impact factor: 3.390

5.  Transient hypercalcemia followed by hypocalcemia in a preterm infant after maternal magnesium sulfate therapy.

Authors:  Takahiro Tominaga; Kazushige Ikeda; Midori Awazu
Journal:  Clin Pediatr Endocrinol       Date:  2021-12-26

6.  Association between the prolonged use of magnesium sulfate for tocolysis and fracture risk among infants.

Authors:  Yung-Hsiang Wen; I-Te Wang; Fang-Ju Lin; Hsing-Yu Hsu; Chung-Hsuen Wu
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.